Editas Medicine Q1 net loss narrows

Editas Medicine

05/05/2026 12:32

Overview

U.S. gene editing firm's Q1 net loss narrowed

Collaboration and other R&D revenue fell yr/yr due to end of prior collaboration

Operating expenses declined, driven by discontinued programs and reduced headcount

Outlook

Editas says current cash will fund operations into Q3 2027

Result Drivers

REVENUE DECLINE - Collaboration and other R&D revenue fell due to recognition of remaining deferred revenue after a collaboration agreement ended in 2025

COST REDUCTIONS - Operating expenses decreased mainly from reduced headcount and discontinuation of the reni-cel program, which lowered clinical and manufacturing costs

NO RESTRUCTURING CHARGES - No restructuring and impairment charges were recorded this quarter, compared to significant charges a year ago tied to discontinued programs

Company press release: ID:nGNXbH2HTS

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Net Income
Beat
-$24.98 mln
-$26.47 mln (10 Analysts)
Q1 Operating Expenses
$27.83 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 3 "hold" and 2 "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Editas Medicine Inc is $4.80, about 60% above its May 4 closing price of $3.00

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)